PROGENICS PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1988-01-01
- Employees
- 105
- Market Cap
- -
- Website
- http://www.progenics.com
Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone
- Conditions
- Interventions
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Progenics Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT03939689
- Locations
- 🇺🇸
Medstar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸City of Hope, Duarte, California, United States
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Progenics Pharmaceuticals, Inc.
- Target Recruit Count
- 208
- Registration Number
- NCT03739684
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California San Francisco - Helen Diller Cancer Center, San Francisco, California, United States
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Progenics Pharmaceuticals, Inc.
- Target Recruit Count
- 385
- Registration Number
- NCT02981368
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of California at San Francisco (UCSF) - Mt. Zion Hospital, San Francisco, California, United States
🇺🇸Washington University Mallinckrodt Institute of Radilogy, Saint Louis, Missouri, United States
An Open-label Extension Study of PSMA ADC 2301 in mCRPC
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Progenics Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02020135
A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Progenics Pharmaceuticals, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT01695044
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Progenics Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01414296
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Progenics Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01414283
- Locations
- 🇺🇸
Progenics Pharmaceuticals, Inc., Tarrytown, New York, United States
Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients
- Conditions
- First Posted Date
- 2003-02-21
- Last Posted Date
- 2008-10-03
- Lead Sponsor
- Progenics Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00055185
- Locations
- 🇺🇸
Beth Israel Medical Center, New York, New York, United States